ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma.

Pediatr Blood CancerSep 10, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)

Himalee S Sabnis, Melinda Pauly, Eric S Schafer et al.

✦ AI-curated · Sources linked

In 30 seconds

This multisite Phase 1 trial assessed the safety and efficacy of everolimus combined with nelarabine, cyclophosphamide, and etoposide in children and young adults with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. The study found an overall response rate of 75% (6/8), with 100% response in the T-ALL cohort.

Key findings

  • The overall response rate was 75% (6/8) among participants.
  • In the T-ALL cohort, the response rate was 100% (5/5).
  • In the T-LL cohort, the response rate was 33% (1/3).
  • No dose-limiting toxicities were reported at the highest dose tested.

Why it matters

The findings suggest that the combination of everolimus with NEC chemotherapy may be a promising approach for achieving remission in relapsed/refractory T-ALL/T-LL, a challenging condition with limited treatment options.

Source

PubMed · PMID 42720434

Published in Pediatr Blood Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.